<h2 data-section-id="17w3vj" data-start="0" data-end="49"><strong>Hematopoietic Stem Cell Transplantation Market</strong></h2>
<p data-start="51" data-end="814">The <a href="https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-market"><strong>Hematopoietic Stem Cell Transplantation (HSCT) market</strong></a> is witnessing significant growth due to rising adoption in hematologic malignancies and expanding use in non-malignant disorders. The 7MM HSCT market was valued at nearly USD 910 million in 2025 and is projected to grow at a CAGR of 12.4% during 2026&ndash;2036. The US accounted for approximately 61% of the total market share, supported by advanced transplant infrastructure and strong reimbursement frameworks. Innovations in conditioning regimens, donor registry expansion, and cord blood banking are further strengthening the market landscape. Emerging therapies such as Orca-T are expected to transform future treatment paradigms with improved immune recovery and reduced transplant-related complications.</p>
<h3 data-section-id="26t1hc" data-start="816" data-end="839"><strong>Key Market Insights</strong></h3>
<ul data-start="840" data-end="1095">
<li data-section-id="zytrrk" data-start="840" data-end="884">7MM market size in 2025: USD 910 million</li>
<li data-section-id="1ansras" data-start="885" data-end="921">Expected CAGR (2026&ndash;2036): 12.4%</li>
<li data-section-id="tvb34x" data-start="922" data-end="966">US contributed 61% of total market share</li>
<li data-section-id="of6rts" data-start="967" data-end="1023">Orca-T projected to generate highest revenue by 2036</li>
<li data-section-id="bvdwr4" data-start="1024" data-end="1095">Growing focus on safer conditioning and precision immune modulation</li>
</ul>
<h2 data-section-id="1uh919s" data-start="1102" data-end="1157"><strong>Hematopoietic Stem Cell Transplantation Epidemiology</strong></h2>
<p data-start="1159" data-end="1874">The epidemiology of <a href="https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-epidemiology-forecast"><strong>Hematopoietic Stem Cell Transplantation</strong></a> reflects a steadily expanding patient pool across the 7MM, with approximately 55,000 HSCT procedures reported in 2025. The US represented nearly 47% of total cases, while EU4 and the UK accounted for 43%, and Japan contributed 10%. <a href="https://www.delveinsight.com/report-store/multiple-myeloma-market"><strong>Multiple myeloma</strong></a>/plasma cell disorders (MM/PCDS) constituted the largest indication segment in the US with 39% of procedures, followed by AML at 17%. In Germany, patients aged 50 years and above represented the largest age group undergoing transplantation, accounting for 60% of procedures. Rising prevalence of hematologic malignancies and broader donor availability continue to support epidemiological expansion globally.</p>
<h3 data-section-id="1s704dq" data-start="1876" data-end="1903"><strong>Epidemiology Highlights</strong></h3>
<ul data-start="1904" data-end="2022">
<li data-section-id="flvd7d" data-start="1904" data-end="1941">Total HSCT procedures in 7MM: 55K</li>
<li data-section-id="muwrii" data-start="1942" data-end="2022">Regional distribution:
<ul data-start="1969" data-end="2022">
<li data-section-id="bwcymz" data-start="1969" data-end="1981">US &ndash; 47%</li>
<li data-section-id="agl0eg" data-start="1984" data-end="2004">EU4 and UK &ndash; 43%</li>
<li data-section-id="10at83v" data-start="2007" data-end="2022">Japan &ndash; 10%</li>
</ul>
</li>
</ul>
<h3 data-section-id="16b3f7e" data-start="2024" data-end="2062"><strong>HSCT Cases by Indication in the US</strong></h3>
<ul data-start="2063" data-end="2165">
<li data-section-id="1a6ukov" data-start="2063" data-end="2080">MM/PCDS &ndash; 39%</li>
<li data-section-id="lqdw0o" data-start="2081" data-end="2094">AML &ndash; 17%</li>
<li data-section-id="16tud05" data-start="2095" data-end="2108">NHL &ndash; 10%</li>
<li data-section-id="t1h57d" data-start="2109" data-end="2126">MDS/MPN &ndash; 10%</li>
<li data-section-id="149by5l" data-start="2127" data-end="2139">ALL &ndash; 6%</li>
<li data-section-id="154gw0w" data-start="2140" data-end="2165">Hodgkin Lymphoma &ndash; 5%</li>
</ul>
<h3 data-section-id="z1vezd" data-start="2167" data-end="2199"><strong>HSCT Cases by Age in Germany</strong></h3>
<ul data-start="2200" data-end="2297">
<li data-section-id="121wh5l" data-start="2200" data-end="2224">Below 18 years &ndash; 10%</li>
<li data-section-id="1jcdgik" data-start="2225" data-end="2246">18&ndash;34 years &ndash; 12%</li>
<li data-section-id="1vfl6vn" data-start="2247" data-end="2268">35&ndash;49 years &ndash; 18%</li>
<li data-section-id="12pvw9h" data-start="2269" data-end="2297">50 years and above &ndash; 60%</li>
</ul>
<h2 data-section-id="1jmlord" data-start="2304" data-end="2355"><strong>Hematopoietic Stem Cell Transplantation Pipeline</strong></h2>
<p data-start="2357" data-end="3117">The <a href="https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-pipeline-insight"><strong>HSCT pipeline</strong></a> is rapidly evolving with the development of advanced cellular therapies, gene replacement approaches, and targeted conditioning platforms aimed at improving transplant outcomes and minimizing toxicity. Companies are focusing on reducing graft-versus-host disease (GvHD), accelerating immune reconstitution, and lowering relapse rates following transplantation. Emerging therapies such as Orca-T, OTL-203, and Iomab-B are expected to redefine future treatment standards through precision cellular engineering and targeted immunotherapy approaches. The pipeline also benefits from integration with CAR T-cell therapies and post-transplant maintenance strategies, creating opportunities for synergistic treatment models in hematologic disorders.</p>
<h3 data-section-id="1dciitl" data-start="3119" data-end="3137"><strong>Emerging Drugs</strong></h3>
<ul data-start="3138" data-end="3452">
<li data-section-id="14f512f" data-start="3138" data-end="3223"><strong data-start="3140" data-end="3168">Orca-T &ndash; Orca Biosystems</strong>
<ul data-start="3171" data-end="3223">
<li data-section-id="bp30bw" data-start="3171" data-end="3198">Mechanism: Cell therapy</li>
<li data-section-id="1et8zaz" data-start="3201" data-end="3223">Route: IV infusion</li>
</ul>
</li>
<li data-section-id="8rrnf7" data-start="3225" data-end="3320"><strong data-start="3227" data-end="3261">OTL-203 &ndash; Orchard Therapeutics</strong>
<ul data-start="3264" data-end="3320">
<li data-section-id="nbx5su" data-start="3264" data-end="3295">Mechanism: Gene replacement</li>
<li data-section-id="1et8zaz" data-start="3298" data-end="3320">Route: IV infusion</li>
</ul>
</li>
<li data-section-id="slhgun" data-start="3322" data-end="3452"><strong data-start="3324" data-end="3382">Iomab-B (I-131 apamistamab) &ndash; Actinium Pharmaceuticals</strong>
<ul data-start="3385" data-end="3452">
<li data-section-id="4q1eae" data-start="3385" data-end="3427">Mechanism: Targeted radioimmunotherapy</li>
<li data-section-id="1et8zaz" data-start="3430" data-end="3452">Route: IV infusion</li>
</ul>
</li>
</ul>
<h3 data-section-id="1reo38a" data-start="3454" data-end="3472"><strong>Approved Drugs</strong></h3>
<ul data-start="3473" data-end="3778" data-is-last-node="" data-is-only-node="">
<li data-section-id="1ai8sfr" data-start="3473" data-end="3522">GRAFAPEX/TRECONDI &ndash; Medac GmbH/Medexus Pharma</li>
<li data-section-id="1bstdi3" data-start="3523" data-end="3549"><a href="https://www.delveinsight.com/report-store/omisirge-sales-forecast-and-market-size-analysis"><strong>OMISIRGE</strong></a> &ndash; Gamida Cell</li>
<li data-section-id="14lncnu" data-start="3550" data-end="3601"><a href="https://www.delveinsight.com/report-store/casgevy-sales-forecast-and-market-size-analysis"><strong>CASGEVY</strong></a> &ndash; <span class="whitespace-normal">Vertex Pharmaceuticals</span></li>
<li data-section-id="rxsfdr" data-start="3602" data-end="3629">ZEMCELPRO &ndash; ExCellThera</li>
<li data-section-id="1b74ufs" data-start="3630" data-end="3667">APHEXDA &ndash; Ayrmid Pharma/BioLineRx</li>
<li data-section-id="wpysyy" data-start="3668" data-end="3722">MabCampath &ndash; <span class="whitespace-normal">Sanofi</span></li>
<li data-section-id="5mqtmh" data-start="3723" data-end="3778" data-is-last-node="">THYMOGLOBULIN &ndash; <span class="whitespace-normal">Sanofi</span></li>
</ul>

Hematopoietic Stem Cell Transplantation Market

Hematopoietic Stem Cell Transplantation Market Infographics

Hematopoietic Stem Cell Transplantation Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape